Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 243-283-8 | CAS number: 19766-89-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Oral, intravenous, and dermal doses of 2-ethylhexanoic acid, the source substance of the read across approach, were absorbed and eliminated rapidly, predominantly in the urine during the first 24 hours following dosing. Washing of the skin promptly after dermal exposure prevented absorption through the skin. Occlusive dermal exposure to the test substance caused considerable damage to the epidermis in the first 24 hours after application, and the dermal absorption values that were observed were considered to be very different from those expected on intact skin. Elimination processes were saturated at the 1000 mg/kg oral dose level. For read across justification please refer to the attached document, IUCLID Chapter 13.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
A read across was performed from the source substance 2 -ethylhexanoic acid to the target substance sodium 2 -ethylhexanoate (for read across justification please refer to attached document, IUCLID Chapter 13).
In a toxicokinetic study with radiolabeled 2 -ethylhexanoic acid (CMA, 1987), groups of eight F344 rats were administered single doses containing 100 or 1000 mg/kg bw of the test substance. In the repeat-dose oral studies, groups of 4 animals were given oral doses of 100 mg/kg bw day of the non-labelled test substance for 14 consecutive days; animals were placed in the metabolism chambers after administration of the radioactive (15th) dose. In the dermal studies, groups of eight animals were administered a single dose of either 100 or 1000 mg/kg bw of the test substance. Intravenous administration was accomplished by injecting 1 mg/kg bw of radioactive test substance mixed with physiological saline into the tail veins of eight animals.
Following a single oral dose of either 100 mg/kg bw or 1000 mg/kg bw, radioactivity was rapidly eliminated in the urine, with excretion of 72-75% of the dose within 24 hours. At the 100 mg/kg bw dose level, 50.4% was eliminated within 8 hr and 75.7% was eliminated in 24 hr. At the 1000 mg/kg bw dose level, means of 19.8% and 72.4% were eliminated in 8 and 24 hr, respectively. Small amounts of14C were detected in urine between 24 and 96 hr (3.6% at the lower dose, 9.8% at the higher dose). Fecal elimination of radioactivity was 12.4% and 6.7% of the 100 mg/kg bw and 1000 mg/kg bw doses, respectively, over the 96 hr collection period. Most was recovered within 24 hours of dosing. The total recovery of radioactivity after single oral administration was 91.7 +/- 2.8% (100 mg/kg bw) and 88.9 +/- 1.0% (1000 mg/kg bw).
Recovery of urine radioactivity from animals repeatedly administered unlabeled test substance, followed by a radioactive dose of 2-ethylehexanoic acid, was 37.9% and 57.3% in 8 and 24 hours, with 3.3% recovery between 24 and 96 hr. Fecal elimination of radioactivity was 14.9% of the dose in these animals, mostly from the 24 hour sample. The total recovery of radioactivity after repeated oral administration of 100 mg/kg bw was 75.5 +/- 4.4%.
Following a dermal dose of 100 mg/kg bw, 10.3% of the14C was excreted in the urine in 8 hr, and 33.2% was eliminated in 24 hours. At a dermal dose of 1000 mg/kg bw, 4.0% was excreted in the urine in 8 hr, and 29.7% was eliminated in 24 hours. An additional 8.5% and 17.0% of the radioactivity was detected in the urine between 24 and 96 hr in the 100 mg/kg bw and 1000 mg/kg bw animals, respectively. Fecal elimination of radioactivity over the course of the study in the dermally exposed animals was 7.5% at the 100 mg/kg bw dose and 7.1% at the 1000 mg/kg bw dose, mostly from the 24-hour fecal samples. The total recovery of radioactivity after dermal application was 49.2 +/-17.3% (100 mg/kg bw) and 53.7 +/-14.2% (1000 mg/kg bw). The low recoveries of [14C] in the dermal studies may be largely due to losses through the exhalation of [14C]CO2. In a similar study of 2-ethylhexanol, which is metabolized exclusively through the formation of 2-EHA, 23 % of the dose (1 mg/kg i.v.) was recovered as [14C]CO2(Deisinger et al. 1994).
Radioactivity was rapidly excreted in the urine following intravenous administration of14C -2-ethylhexanoic acid. Within 8 hr, 47.9% was excreted in the urine, and 64.2% was excreted by 24 hr. Another 2.4% was excreted between 24 and 96 hours. Fecal elimination was 3.6% of the dose. The total recovery of radioactivity was 70.2 +/-4.2%.
Blood levels after intravenous injection appear to decay in a triphasic manner with half lives of 0.19 ± 0.11 hr, 6.6 ± 3.9 hr, and 117 ± 47 hr. After oral administration, peak blood levels occurred after 15 to 30 minutes and also declined in a triphasic manner. Half-lives after oral administration were similar to what had been estimated from intravenous administration (0.32 ± 0.04 hr, 6.8 ± 3.5 hr, and 98.3 ± 32.8 hr). Dermal application resulted in slower absorption with peak blood levels occurring 5.7 ± 0.4 hr after application and an absorption half life of 3.2 ± 0.1 hr. Elimination of14C was biphasic with half-lives of 4.2 ± 0.2 hr and 251 ± 135 hr. The major urinary metabolites were the glucuronide of 2-ethylhexanoic acid, 2-ethyl-1,6-hexanedioic acid, 2-ethyl-5-hydroxyhexanoic acid, 2-ethyl-6-hydroxyhexanoic acid, and ethylketohexanoic acid. From 2-7% was excreted as unmetabolized 2-ethylhexanoic acid following all oral and dermal dosing regimens. No sulphate derivatives were detected. Evidence for metabolism via β-oxidation was also found, consistent with the incorporation of 2-ethylhexanoic acidinto normal cellular intermediary metabolism.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.